Catalent Pharma Solutions has completed the second phase of a clinical storage expansion program at its facility in Kansas City, Missouri, US.
The firm is engaged in providing advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
The $5.5m two-year expansion program is a part of the firm’s plan to increase the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.
The program has resulted in expanded highly-potent, cytotoxic and cold storage clinical drug packaging capabilities at the facility. It
Additionally, the expansion, which includes a new Drug Enforcement Administration (DEA) Schedule I and II controlled substance vault, added 3,600ft² of storage as well as controlled temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations.
To ensure the security and integrity of samples in storage, the company has also added a new sampling room and an emergency generator at the facility.
Catalent Pharma Solutions Clinical Supply Services general manager Kevin Economos said: “Catalent customers have benefitted from our integrated analytical, oral solid manufacturing, and clinical supply services which our Kansas City campus has offered continuously for over 18 years.
“These latest expansions are critical enablers to our customers’ continued growth that reinforce our comprehensive global network, and enhance Catalent’s role as a market leader in the clinical supply industry.”
The services provided by the company at the 450,000ft² Kansas City facility include development and analytical support, as well as packaging and distribution.
Recently, Catalent completed expansion at two of its other clinical supply facilities in Philadelphia and Singapore.
At the Philadelphia facility, the firm has invested $5.5m to provide additional clinical packaging and storage capacity.
With the investment, the firm has increased the facility’s pallet space by 40% for both refrigerated and ambient clinical storage.
The investment also included additional cold chain packaging areas, and a new clinical label control area.